Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on November 17, 2016. The report addresses a regulatory notice regarding the company's continued listing status on the Nasdaq Global Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance: the bid price for the Company's common stock closed below the minimum $1.00 per share requirement for the last 30 consecutive business days.
Material Changes
The material event reported is the receipt of a deficiency letter from the Nasdaq Listing Qualifications Department. This notification cites a failure to satisfy Nasdaq Listing Rule 5450(a)(1) due to the sustained low bid price of the common stock.
Guidance, Outlook, and Risks
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending on May 16, 2017, to regain compliance.
- Remediation Strategy: To regain compliance, the stock must close at $1.00 or more for a minimum of 10 consecutive business days. Management may consider effecting a reverse stock split if appropriate.
- Risks: There is no assurance that the Company will be able to regain compliance. Failure to do so could result in delisting, though the deficiency letter does not cause immediate delisting.
Investor Verification Checklist
- Verify the current closing bid price of Cerulean Pharma Inc. common stock.
- Monitor the company's progress toward the May 16, 2017 compliance deadline.
- Watch for announcements regarding a potential reverse stock split.
- Review subsequent filings for updates on the Nasdaq deficiency status.